GlassScriptPhysician profile
Maria D Chapa
NPI 1457443012
$7,812.44
in general payments reported to CMS, 2019-2025
38 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $479 · 2021: $1,395 · 2022: $1,717 · 2023: $1,479 · 2024: $937 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,534 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,534.15 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,454.22 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,216.73 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,020.93 | 2019-2024 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $675.08 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $414.85 | 2019-2020 | |
| Pfizer INC. | $325.89 | 2019-2025 | |
| Amarin Pharma, INC. | $246.55 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $208.26 | 2021 | |
| Esperion Therapeutics, INC. | $196.64 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $180.16 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $179.55 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $177.52 | 2023-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Neurelis, INC. | $152.01 | 2022-2023 | Valtoco |
| Takeda Pharmaceuticals U.S.A., INC. | $124.99 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $123.81 | 2023 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $116.12 | 2022 | |
| Lundbeck LLC | $110.72 | 2022-2023 | Abilify Maintena, Rexulti |
| Exact Sciences Corporation | $84.86 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $79.37 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Amgen INC. | $75.02 | 2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $72.35 | 2022-2023 | |
| Genentech USA, INC. | $65.53 | 2019-2021 | |
| Boston Scientific Corporation | $64.75 | 2019-2024 | Ams 700 |
| Medtronic, INC. | $60.51 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $59.64 | 2022-2023 | Keveyis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.85 | 2022 | |
| Shire North American Group INC | $38.48 | 2019 | |
| Merck Sharp & Dohme LLC | $36.95 | 2020-2021 | |
| Inspire Medical Systems, INC. | $32.77 | 2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $29.66 | 2022-2023 | Quviviq |
| Actelion Pharmaceuticals US, INC. | $26.92 | 2024 | Opsumit |
| Nevro Corp. | $22.97 | 2024 | Senza |
| Kyowa Kirin, INC. | $18.01 | 2024 | Crysvita |
| Mannkind Corporation | $15.97 | 2022 | |
| Vertical Pharmaceuticals, LLC | $14.26 | 2019 | |
| Si-Bone, INC. | $14.01 | 2025 | |
| Glaxosmithkline, LLC. | $12.49 | 2020 | |
| Currax Pharmaceuticals LLC | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Chapa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.